<DOC>
	<DOCNO>NCT00529386</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy intraprostatic injection Botox treatment men diagnose chronic nonbacterial prostatitis/chronic pelvic pain syndrome ( CP/CPPS ) .</brief_summary>
	<brief_title>Botox Chronic Prostatitis/Chronic Pelvic Pain Syndrome ( CP/CPPS )</brief_title>
	<detailed_description>This blind prospective randomize design compare efficacy safety intraprostatic Botox vs. intraprostatic lidocaine injection , optional open label extension . Men clinical diagnosis chronic nonbacterial prostatitis/CPPS treat intraprostatic Botox™ 1 % lidocaine follow 12 week ( primary efficacy analysis ) , 24 week ( long term follow-up ) responder . An open label extension offer non-responders . A total 40 male enrol . There seven ( 7 ) research clinic visit two phone contact : Visit 1 ( screen ) , Visit 2 ( baseline/treatment ) , Visit 3 ( 2-week safety evaluation - clinic contact ) , Visit 4 ( 4-week safety evaluation - phone contact ) , Visit 5 ( 6-week interim efficacy/safety ) , Visit 6 ( 12-week primary endpoint evaluation ) , Visit 7 ( 14-week clinic follow ) , Visit 8 ( 16 week phone contact ) Visit 9 ( 24-week clinic close ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>1 . Participant sign dated appropriate Informed Consent document . 2 . Participant must ≥ 18 year age . 3 . Participant clinical diagnosis chronic nonbacterial prostatitis ( chronic pelvic pain syndrome ) ( CPPS ) define symptom discomfort pain perineal pelvic region least past 3 month without evidence bacterial infection . 4 . Participants must report ejaculatory pain and/or perineal discomfort . 5 . Participants must pain discomfort localize perineum prostate physical examination . 6 . Participants must aggregate score great equal 15 National Institutes Health chronic prostatitis symptom index ( NIHCPSI ) . 7 . Participant must &gt; 8 pain domain subscore NIHCPSI . 8 . Participant must empiric treatment 4 week fluoroquinolone , subsequently fail antibiotic therapy . 1 . Participant history prostate , bladder urethral cancer . 2 . Participant inflammatory bowel disease ( Crohn 's disease ulcerative colitis , irritable bowel syndrome ) . 3 . Participant undergone pelvic radiation systemic chemotherapy . 4 . Participant undergone intravesical chemotherapy . 5 . Participant treat unilateral orchialgia without pelvic symptom . 6 . Participant current urethral stricture and/or bladder stone . 7 . Participant neurological disease disorder affect bladder . 8 . Participant neurological impairment psychiatric disorder prevent understanding consent ability comply protocol . 9 . Participant document UTI within last 3 month . 10 . Participant evidence facultative Gram negative enterococcus value ≥ 1000 CFU/ml midstream urine ( VB2 ) . 11 . Participant previous intraprostatic injection Botox . 12 . Participant currently enrol investigational study . 13 . Participant interested future fertility/fathering child . 14 . Participant urinary retention ( PVR &gt; 200cc ) . 15 . Participant prostate surgery past 3 month . 16 . Participant minimally invasive surgical therapy BPH . 17 . Participant cystostomy nephrostomy . 18 . Participant penile urinary sphincter implant . 19 . Participant previous rectal surgery , current rectal disease perirectal inflammatory disorder except hemorrhoidectomy . 20 . Participant PSA &gt; 10 ng/ml ( PSA range 410 , biopsy PI discretion ( deferral ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>prostatitis</keyword>
	<keyword>Botox</keyword>
</DOC>